

DOCKET NO.: UBCV-0004/ 97-109
Application No.: 09/189,415
Office Action Dated: November 8, 2005

**PATENT
REPLY FILED UNDER EXPEDITED
PROCEDURE PURSUANT TO
37 CFR § 1.116**

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1-6. (Cancelled)

7. (Previously presented) An isolated polypeptide comprising the amino acid sequence as set forth in SEQ ID NO: 11.

8-51. (Cancelled)

52. (Previously presented) A pharmaceutical composition comprising a polypeptide that comprises the polypeptide of claim 7 or 63 in a pharmaceutically acceptable carrier.

53-61. (Cancelled)

62. (Previously presented) A Tir polypeptide fragment comprising the amino acid sequence set forth in SEQ ID NO: 7.

63. (Previously presented) An isolated Tir polypeptide that consists of 8 consecutive amino acids of SEQ ID NO: 11.

64. (Previously presented) The isolated Tir polypeptide of claim 63 wherein the Tir polypeptide fragment comprises the amino acid sequence set forth in SEQ ID NO: 7.

65. (Previously presented) A fusion protein comprising an isolated Tir polypeptide that comprises the amino acid sequence of SEQ ID NO: 11 fused to a non-Tir protein sequence.

66. (Previously presented) The fusion protein of claim 64 wherein the fusion protein comprises a cleavage site located between the Tir polypeptide and the non-Tir protein sequence.

67. (Previously presented) The fusion protein of claim 65 wherein the non-Tir protein sequence is an immunoglobulin (Ig) Fc domain.

DOCKET NO.: UBCV-0004/97-109
Application No.: 09/189,415
Office Action Dated: November 8, 2005

**PATENT
REPLY FILED UNDER EXPEDITED
PROCEDURE PURSUANT TO
37 CFR § 1.116**

68. **(Previously presented)** The fusion protein of claim 65 wherein the non-Tir protein sequence is a marker polypeptide selected from the group consisting of an enzyme, a fluorescent protein, and a luminescent protein.

69-74. **(Cancelled)**

75. **(Previously presented)** An isolated nucleic acid molecule which encodes a Tir protein comprising the amino acid sequence of SEQ ID NO: 11 or an amino acid sequence variant which is at least 95% identical to an amino acid sequence as set forth in SEQ ID NO: 11, wherein the variant has the ability to induce an immune response in a host to a Tir-producing organism.